In patients with chronic renal failure, secondary hyperparathyroidism (sHPT) is a common problem requiring surgical parathyroidectomy (PTX) if medical treatment with active vitamin D and calcimimetics fails. To minimize the risk for recurrence, we perform total PTX (tPTX) without autotransplantation. From October 1997 to January 2004, 46 patients (31 men and 15 women) underwent tPTX without autotransplantation (median age 51 years; range 19–80 years; median dialysis time before PTX 5 years; range 0–25 years). Indications for PTX were hyperparathyroid bone disease in 41 cases and calciphylaxis in 5 cases. Postoperatively, all patients were supplemented with vitamin D analogues, both calcitriol and cholecalciferol. Patients were followed up for 4–107 months (median 63 months). Although tPTX was intended in all cases, we saw recurrent or persistent hyperparathyroidism in 26% and supernumerary glands in 15% of cases. In 7 patients (15%), five or more glands were documented and in another four suspected confirming the clinical relevance of intraoperative parathyroid hormone (PTH) measurement. In our study, the positive predictive value of a low intraoperative PTH (<20 pg/ml) for a successful tPTX was 92%. 15 patients received a renal transplant after tPTX without autotransplantation. Here, an uncomplicated hypocalcaemia was noted in 3 patients. Last available calcium levels were between 1.72 and 2.66 mmol/l (median 2.35 mmol/l). After follow-up, active vitamin D was given in a median daily dose of 0.5 μg calcitriol (range 0–2.5 μg/day). There was no evidence of clinical bone disease and no pathological fractures after tPTX after a median observation period of 63 months. tPTX still offers the highest percentage of cure for sHPT, it is safe and postoperatively easily manageable. It allows for adequate supplementation with active vitamin D, and it is the most cost-effective procedure. It should be reconsidered an option for the treatment of sHPT.

Foley RN, Parfrey PS, Sarnak MJ: Cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;38(suppl):S112–S119.
Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607–617.
Rostand SG, Drueke T: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999;56:383–392.
Block GA, Port FK: Re-evaluation of risk associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendation for a change in management. Am J Kidney Dis 2000;35:1226–1237.
Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO4, CaxPO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131–2138.
Stracke S, Jehle PM, Sturm D, Schoenberg MH, Widmaier U, Beger HG, Keller F: Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Am J Kidney Dis 1999;33:304–311.
Valderrabano F, Berthoux FC, Jones EH, Mehls O: Report on management of renal failure in Europe, XXV, 1994 end-stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Nephrol Dial Transplant 1996;11(suppl 1):2–21.
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516–1525.
Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800–807.
de Francisco AL: Secondary hyperparathyroidism: review of disease and its treatment. Clin Ther 2004;26:1976–1993.
Stanbury SW, Lumb GA, Nicholson WF: Elective subtotal parathyroidectomy for renal hyperparathyroidism. Lancet 1960;i:793–799.
Koonsman M, Hughes K, Dickerman R, Brinker K, Dunn E: Parathyroidectomy in chronic renal failure. Am J Surg 1994;168:631–634.
Rothmund M, Wagner PK, Schark C: Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg 1991;15:745–750.
Ritz E: Which is the preferred treatment of advanced hyperparathyroidism in a renal patient? II. Early parathyroidectomy should be considered as the first choice. Nephrol Dial Transplant 1994;9:1819–1821.
Drueke TB, Zingraff J: The dilemma of parathyroidectomy in chronic renal failure. Curr Opin Nephrol Hypertens 1994;3:386–395.
Korzets Z, Magen H, Kraus L, Bernheim J, Bernheim J: Total parathyroidectomy with autotransplantation in haemodialysed patients with secondary hyperparathyroidism – should it be abandoned? Nephrol Dial Transplant 1987;2:341–346.
Henry JF, Denizot A, Audiffret J, France G: Results of reoperations for persistent or recurrent secondary hyperparathyroidism in hemodialysis patients. World J Surg 1990;14:303–306.
Hampl H, Steinmuller T, Stabell U, Klingenberg HJ, Schnoy N, Neuhaus P: Recurrent hyperparathyroidism after total parathyroidectomy and autotransplantation in patients with long-term hemodialysis. Miner Electrolyte Metab 1991;17:256–260.
Higgins RM, Richardson AJ, Ratcliffe PJ, Woods CG, Oliver DO, Morris PJ: Total parathyroidectomy alone or with autograft for renal hyperparathyroidism? Q J Med 1991;79:323–332.
Gagne ER, Urena P, Leite-Silva S, Zingraff J, Chevalier A, Sarfati E, Dubost C, Drueke TB: Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992;3:1008–1017.
Neonakis E, Wheeler MH, Krishnan H, Coles GA, Davies F, Woodhead JS: Results of surgical treatment of renal hyperparathyroidism. Arch Surg 1995;130:643–648.
Ockert S, Willeke F, Richter A, Jonescheit J, Schnuelle P, Van Der Woude F, Post S: Total parathyroidectomy without autotransplantation as a standard procedure in the treatment of secondary hyperparathyroidism. Langenbecks Arch Surg 2002;387:204–209.
Saunders RN, Karoo R, Metcalfe MS, Nicholson ML: Four gland parathyroidectomy without reimplantation in patients with chronic renal failure. Postgrad Med J 2005;81:255–258.
Lorenz K, Ukkat J, Sekulla C, Gimm O, Brauckhoff M, Dralle H: Total parathyroidectomy without autotransplantation for renal hyperparathyroidism: experience with a qPTH-controlled protocol. World J Surg 2006;30:743–751.
Farrington K, Varghese Z, Chan MK, Fernando ON, Baillod RA, Sweny P, Moorhead JF: How complete is a total parathyroidectomy in uraemia? Br Med J 1987;294:743.
Kaye M, D’Amour P, Henderson J: Elective total parathyroidectomy without autotransplant in end-stage renal disease. Kidney Int 1989;35:1390–1399.
Ljutic D, Cameron JS, Ogg CS, Turner C, Hicks JA, Owen WJ: Long-term follow-up after total parathyroidectomy without parathyroid reimplantation in chronic renal failure. QJM 1994;87:685–692.
Hampl H, Steinmuller T, Frohling P, Naoum C, Leder K, Stabell U, Schnoy N, Jehle PM: Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure. Miner Electrolyte Metab 1999;25:161–170.
Stratton J, Simcock M, Thompson H, Farrington K: Predictors of recurrent hyperparathyroidism after total parathyroidectomy in chronic renal failure. Nephron Clin Pract 2003;95:c15–c22.
Ding C, Buckingham B, Levine MA: Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB. J Clin Invest 2001;108:1215–1220.
Gunther T, Chen ZF, Kim J, Priemel M, Rueger JM, Amling M, Moseley JM, Martin TJ, Anderson DJ, Karsenty G: Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 2000;406:199–203.
Wang CA: The anatomic basis of parathyroid surgery. Ann Surg 1976;183:271–275.
Akerstrom G, Malmaeus J, Bergstrom R: Surgical anatomy of human parathyroid glands. Surgery 1984;95:14–21.
Numano M, Tominaga Y, Uchida K, Orihara A, Tanaka Y, Takagi H: Surgical significance of supernumerary parathyroid glands in renal hyperparathyroidism. World J Surg 1998;22:1098–1103.
Pattou FN, Pellissier LC, Noel C, Wambergue F, Huglo DG, Proye CAG: Supernumerary parathyroid glands: frequency and surgical significance in treatment of renal hyperparathyroidism. World J Surg 2000;24:1330–1334.
Felsenfeld AJ, Harrelson JM, Gutman RA, Wells SA Jr, Drezner MK: Osteomalacia after parathyroidectomy in patients with uremia. Ann Intern Med 1982;96:34–39.
Zingraff J, Drueke T, Gueris J, Jungers P, Crosnier J: Severe osteomalacia following subtotal parathyroidectomy in patients with uremia treated with hemodialysis. J Urol Nephrol 1978;84:681–682.
Gal-Moscovici A, Popovtzer MM: Parathyroid hormone-independent osteoclastic resorptive bone disease: a new variant of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 2002;17:620–624.
Marx SJ: Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 2000;343:1863–1875.
Shaha AR, Burnett C, Jaffe BM: Parathyroid autotransplantation during thyroid surgery. J Surg Oncol 1991;46:21–24.
Drezner MK, Neelon FA, Jowsey J, Lebovitz HE: Hypoparathyroidism: a possible cause of osteomalacia. J Clin Endocrinol Metab 1977;45:114–122.
Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al: The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36–45.
Joy MS, Karagiannis PC, Peyerl FW: Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 2007;13:397–411.
Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, D’Souza R, et al: The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007;11:iii, xi–xiii, 1–167.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.